Editorial: Small molecules and biologics for future purinergic therapeutics.
Editorial: Small molecules and biologics for future purinergic therapeutics.
复制标题
社论：未来嘌呤能疗法的小分子和生物制剂。
DOI：
10.1007/s11302-023-09964-9
复制
发表时间：
2023
影响因子：
3.5
通讯作者：
Salvemini,Daniela
中科院分区：
文献类型：
--
作者：
Jacobson,KennethA;Salvemini,Daniela
受体激动剂和拮抗剂以及嘌呤能信号传导的其他调节剂具有作为多种疾病和病症的新疗法的潜力。本期特刊重点关注正在进行临床试验或朝该方向发展的化合物或方法。它旨在作为发现和开发新的小分子嘌呤能药物的选定努力的最新描述。
Receptor agonists and antagonists and other modulators of purinergic signalling have potential as novel therapeutics for a broad range of diseases and conditions. This special issue focuses on compounds or approaches that are either in clinical trials or headed in that direction. It is intended to serve as an up-to-date description of selected efforts to discover and develop new small molecular purinergic drugs.